Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy

Therapeutic Cancer Vaccines: Current Status and Moving Forward

(2012) J. Schlom   JNCI-Journal of the National Cancer Institute

Normalization of tumour blood vessels improves the delivery of nanomedicines in a size-dependent manner

(2012) Vikash P. Chauhan et al.   Nature Nanotechnology

Tumor-targeted TNF  stabilizes tumor vessels and enhances active immunotherapy

(2012) A. Johansson et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Receptor Tyrosine Kinases and TLR/IL1Rs Unexpectedly Activate Myeloid Cell PI3Kγ, A Single Convergent Point Promoting Tumor Inflammation and Progression

(2011) Michael C. Schmid et al.   CANCER CELL

HRG Inhibits Tumor Growth and Metastasis by Inducing Macrophage Polarization and Vessel Normalization through Downregulation of PlGF

(2011) Charlotte Rolny et al.   CANCER CELL

Polarization of Tumor-Associated Macrophages: A Novel Strategy for Vascular Normalization and Antitumor Immunity

(2011) Yuhui Huang et al.   CANCER CELL

Increased Survival of Glioblastoma Patients Who Respond to Antiangiogenic Therapy with Elevated Blood Perfusion

(2011) A. G. Sorensen et al.   CANCER RESEARCH

CXCL12/CXCR4 Blockade Induces Multimodal Antitumor Effects That Prolong Survival in an Immunocompetent Mouse Model of Ovarian Cancer

(2011) E. Righi et al.   CANCER RESEARCH

Tumor-infiltrating immune cells and prognosis: the potential link between conventional cancer therapy and immunity

(2011) Caroline Jochems et al.   EXPERIMENTAL BIOLOGY AND MEDICINE

Shifting the equilibrium in cancer immunoediting: from tumor tolerance to eradication

(2011) Sergio A. Quezada et al.   IMMUNOLOGICAL REVIEWS

Consequence of dose scheduling of sunitinib on host immune response elements and vaccine combination therapy

(2011) Benedetto Farsaci et al.   INTERNATIONAL JOURNAL OF CANCER

RIBBON-1: Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of Chemotherapy With or Without Bevacizumab for First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative, Locally Recurrent or Metastatic Breast Cancer

(2011) Nicholas J. Robert et al.   JOURNAL OF CLINICAL ONCOLOGY

Molecular mechanisms and clinical applications of angiogenesis

(2011) Peter Carmeliet et al.   NATURE

Leukocyte Complexity Predicts Breast Cancer Survival and Functionally Regulates Response to Chemotherapy

(2011) David G. DeNardo et al.   Cancer Discovery

Antiangiogenic Agents Can Increase Lymphocyte Infiltration into Tumor and Enhance the Effectiveness of Adoptive Immunotherapy of Cancer

(2010) R. K. Shrimali et al.   CANCER RESEARCH

Phase III Study of Bevacizumab Plus Docetaxel Compared With Placebo Plus Docetaxel for the First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer

(2010) David W. Miles et al.   JOURNAL OF CLINICAL ONCOLOGY

Lessons From the Adjuvant Bevacizumab Trial on Colon Cancer: What Next?

(2010) Eric Van Cutsem et al.   JOURNAL OF CLINICAL ONCOLOGY

HIF-1α regulates function and differentiation of myeloid-derived suppressor cells in the tumor microenvironment

(2010) Cesar A. Corzo et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm

(2010) Subhra K Biswas et al.   NATURE IMMUNOLOGY

Therapeutic Cancer Vaccines in Prostate Cancer: The Paradox of Improved Survival Without Changes in Time to Progression

(2010) R. A. Madan et al.   ONCOLOGIST

Myeloid Cells in the Tumor Microenvironment: Modulation of Tumor Angiogenesis and Tumor Inflammation

(2010) Michael C. Schmid et al.   Journal of Oncology

Vascular normalization in Rgs5-deficient tumours promotes immune destruction

(2008) Juliana Hamzah et al.   NATURE